Articles About amgen
January 31, 2014
Amgen's cholesterol-fighting drug evolocumab has met its goal in its fifth late-stage clinical trial, putting the company well ahead of competitors.
January 27, 2014
Amgen has a 62 percent positive surprise history, having topped the whisper in 32 of the 52 earnings reports for which we have data.
January 24, 2014
In 2013, Amgen agreed to acquire Onyx Pharmaceuticals in a cash deal worth approximately $10.4 billion.